Arcadia Biosciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Product | $1,455 | $1,306 | $2,655 | $2,293 |
| Total revenues | 1,455 | 1,306 | 2,655 | 2,293 |
| Operating expenses (income): | ||||
| Cost of revenues | 824 | 633 | 1,506 | 1,104 |
| Research and development | 9 | 10 | 9 | 16 |
| Gain on sale of intangible assets | — | (4,000) | (750) | (4,000) |
| Impairment of property and equipment | — | — | — | 36 |
| Change in fair value of contingent consideration | (1,000) | — | (2,000) | — |
| Selling, general and administrative | 2,123 | 2,683 | 3,861 | 4,745 |
| Total operating expenses | 1,956 | (674) | 2,626 | 1,901 |
| (Loss) income from operations | (501) | 1,980 | 29 | 392 |
| Interest income | 9 | 150 | 216 | 195 |
| Credit loss | (4,489) | — | (4,489) | — |
| Other income | 1,071 | 150 | 1,071 | 153 |
| Change in fair value of common stock warrant and option liabilities | (548) | (430) | 1,314 | 163 |
| Net (loss) income from continuing operations | (4,458) | 1,850 | (1,859) | 903 |
| Net loss from discontinued operations | — | (789) | — | (2,265) |
| Net (loss) income attributable to common stockholders | $(4,458) | $1,061 | $(1,859) | $(1,362) |
| Net (loss) income per share attributable to common stockholders: | ||||
| Basic and diluted from continuing operations | $(3.26) | $1.36 | $(1.36) | $0.66 |
| Basic and diluted from discontinued operations | $— | $(0.58) | $— | $(1.66) |
| Net (loss) income per basic share attributable to common stockholders | $(3.26) | $0.78 | $(1.36) | $(1.00) |
| Weighted-average number of shares used in per share calculations: | ||||
| Basic and diluted | 1,367,040 | 1,362,840 | 1,366,553 | 1,362,249 |
| Other comprehensive income, net of tax | ||||
| Unrealized gains on available-for-sale securities | $— | $31 | $— | $91 |
| Reclassification adjustment for gains on available-for-sale securities included in net (loss) income | — | (111) | — | (111) |
| Change in unrealized gains on available-for-sale securities | $— | $(80) | $— | $(20) |
| Comprehensive (loss) income | $(4,458) | $981 | $(1,859) | $(1,382) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.